Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Androgen-deprivation Therapy (ADT) Clear all
Completed Not applicable Interventional Results available

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

NCT01542021
View directory record Official record
Conditions
Prostate Cancer, Prostatic Adenocarcinoma
Interventions
degarelix injection, androgen deprivation therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 10, 2026, 8:31 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 2 Interventional Results available

EXTEND Exercise Trial

NCT02256111
View directory record Official record
Conditions
Non-metastatic, Hormone naïve Prostate Cancer
Interventions
Enzalutamide, Androgen deprivation therapy, Supervised exercise training
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 10, 2026, 8:31 PM EDT
Recruiting Phase 3 Interventional

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047
View directory record Official record
Conditions
Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions
Apalutamide, Androgen Deprivation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Recruiting Phase 2 Interventional

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247
View directory record Official record
Conditions
Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
Drug · Behavioral · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
30 Years to 79 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

NCT01436968
View directory record Official record
Conditions
Prostate Cancer
Interventions
Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir
Biological
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2030
U.S. locations
72
States / cities
Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Not applicable Interventional Results available

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

NCT01040624
View directory record Official record
Conditions
Prostate Cancer
Interventions
> 15% risk of + LN
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 10, 2026, 8:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

Behavioral Exercise Training to Reduce Cardiovascular Disease Risk

NCT06237179
View directory record Official record
Conditions
Prostate Cancer, Supportive Care
Interventions
Exercise Training Intervention, Healthy Living Education
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Terminated Phase 2 Interventional

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

NCT05676463
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
MRI-guided Intensity-Modulated Radiation Therapy, Antiandrogen Therapy, PSMA PET Scan, Computed Tomography, Magnetic Resonance Imaging, Bone Scan, Biospecimen Collection, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Terminated Phase 2 Interventional

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

NCT00521781
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Abraxane, Leuprolide, Bicalutamide
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 10, 2026, 8:31 PM EDT
Completed No phase listed Observational

Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer

NCT03386812
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 89 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 10, 2026, 8:31 PM EDT
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 2 Interventional Results available

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

NCT01120236
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Bicalutamide, Cixutumumab, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Pharmacological Study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
169
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 10, 2026, 8:31 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853
View directory record Official record
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
Capivasertib, Placebo, Abiraterone Acetate
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Tucson, Arizona • La Jolla, California • Orange, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

NCT00838201
View directory record Official record
Conditions
Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 10, 2026, 8:31 PM EDT
Terminated No phase listed Observational

Predicting Cognitive Decline From Androgen Deprivation Therapy

NCT05820932
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood-based assay, Cognitive assessments, Quality of Life Surveys
Genetic · Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 4 Interventional Results available

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

NCT00470834
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
dutasteride, placebo, bicalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 90 Years · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
47
States / cities
Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 10, 2026, 8:31 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Contributions to Hypertension With Androgen Deprivation Therapy

NCT05700903
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Completed Phase 1 Interventional

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

NCT00096551
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 10, 2026, 8:31 PM EDT
Terminated Phase 2 Interventional Results available

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
Behavioral · Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 10, 2026, 8:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

NCT05169970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 10, 2026, 8:31 PM EDT
Recruiting Not applicable Interventional

Role of Race in Nutritional Approach in Men on ADT

NCT06682390
View directory record Official record
Conditions
Prostate Cancer Metastatic Disease
Interventions
Hypocaloric anti-inflammatory diet
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 10, 2026, 8:31 PM EDT